CRISPR Therapeutics CASGEVY Sales Reach $99 Million

The Tip Desk · November 3, 2026 · 3 min read

The gene-editing company posted $99 million of CASGEVY revenue in the third quarter, nearly six times the year-earlier quarter, as pediatric approvals widened the eligible population.

CRISPR Therapeutics (CRSP) reported CASGEVY revenue of $99 million in the third quarter of 2026, up 30% from the prior quarter and nearly six times the third quarter of 2025.

The world’s first approved CRISPR-based therapy, used for sickle cell disease and transfusion-dependent beta thalassemia, had generated $76 million in the second quarter after $43 million in the first. The company said twice as many patients had initiated CASGEVY in the first nine months of 2026 as in all of 2025, with more than 750 patients treated worldwide.

Access for younger patients expanded during the quarter. In July, the FDA approved CASGEVY for children 2 years of age and older with sickle cell disease or transfusion-dependent beta thalassemia, the first genetic therapy for that age group, and multiple children have since started treatment in the United States. The United Arab Emirates and Bahrain also approved the product for children 2 and older, and the U.K. MHRA approved it for children 5 and older with severe disease. CASGEVY is approved in 39 countries for patients 12 and older, with younger-child approvals in five of those countries.

Chairman and Chief Executive Officer Samarth Kulkarni said CASGEVY is reaching more patients and that the company is entering a pivotal period for its pipeline.

The FDA granted Regenerative Medicine Advanced Therapy designations to CTX310 for severe hypertriglyceridemia and elevated LDL-C. RMAT designation provides Fast Track and Breakthrough Therapy benefits, including early FDA interactions and potential eligibility for priority review. In August, the company presented Phase 1a durability data showing that a single course of CTX310 produced mean reductions from baseline of 79% in ANGPTL3, 48% in triglycerides, and 53% in LDL-C at the highest dose, sustained through one year of follow-up, with no treatment-related serious adverse events. Phase 1b data in severe hypertriglyceridemia are scheduled for a late-breaking oral presentation at AHA Scientific Sessions on November 9.

Enrollment completed in the Phase 2 trial of CTX611, a long-acting siRNA targeting Factor XI, in patients undergoing total knee arthroplasty, with an update expected in the second half of 2026. CRISPR Therapeutics will lead global Phase 3 development. Phase 1 data for zugo-cel in systemic sclerosis are set for ACR Convergence on November 8.

Total revenue was $12.7 million for the three months ended September 30, 2026, including $12.3 million of collaboration revenue and $0.3 million of grant revenue. Net loss was $111.4 million, or $1.15 a share, compared with a net loss of $106.4 million, or $1.17 a share, a year earlier.

Research and development expenses were $71.9 million, up from $58.9 million, which the company attributed primarily to higher external R&D and sublicense fees, offset by lower employee-related costs. Acquired in-process R&D expenses were $11.7 million, primarily a development milestone under the Sirius Agreement; none were recognized in the third quarter of 2025. General and administrative expenses were $17.9 million. Collaboration expense, net, fell to $41.3 million from $57.1 million a year earlier, with the decrease primarily attributable to an increase in the company’s share of CASGEVY revenue.

Cash, cash equivalents, and marketable securities were $2,276.6 million as of September 30, 2026, compared with $1,975.8 million at year-end 2025. The company said the increase was driven primarily by $585.4 million of net proceeds from convertible senior notes issued in March 2026, offset by operating expenses.

The company appointed Sivakesava Sakhamuri as Chief Technical Officer and A.J. Silver as Chief Financial Officer, succeeding Raju Prasad.